Inhibitors of phospholipase enzymes

A compound of the formulae:

• wherein:
• R1 and R1′ are independently selected from H, halogen, —CF3, —OH, —C1-C10 alkyl, —S— C1-C10 alkyl, C1-C10 alkoxy, —CN, —NO2, —NH2, —HN(C1-C6), —N(C1-C6)2, phenyl, —O-phenyl, —S-phenyl, benzyl, —O-benzyl, —S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, —NO2, —NH2, —CN, —CF3, or —OH;
• or a moiety of the formulae:
• R6 is selected from H, C1-C6 alkyl, C1-C6 alkoxy, —C(O)CH3 phenyl, —O-phenyl benzyl, —O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, —NO2, —NH2, —CN, —CF3, or —OH;
• R7 is selected from —(CH2)n—COOH, —(CH2)n—N—(C1-C6 alkyl)2, —(CH2)n—NH—(C1-C6 alkyl), —CF3, C1-C6 alkyl, C3-C5 cycloalkyl, C1-C6 alkoxy, —NH—(C1-C6 alkyl), —N—(C1-C6 alkyl)2, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, (CH2)nphenyl, phenyl, —O-phenyl, benzyl, —O-benzyl, adamantyl, —(CH2)n-phenyl-O-phenyl, —(CH2)n-phenyl-CH2-phenyl, —(CH2)n—O-phenyl-CH2-phenyl, and —(CH2)n-phenyl—(O—CH2-phenyl)2, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, —NH2, —NO2, —CF3, CO2H, or —OH;
• R2 is selected from H, halogen, —CF3, —OH, —C1-C10 alkyl, C1-C10 alkoxy, —CHO, —CN, —NO2, —NH2, —NH—C1-C6 alkyl, —N(C1-C6 alkyl)2, —N—SO2—C1-C6 alkyl, or —SO2—C1-C6 alkyl;
• R3 is selected from H, —CF3, C1-C6 lower alkyl, C1-C6 lower alkoxy, C3-C10 cycloalkyl, —C1-C6 alkyl, —C3-C10 cycloalkyl, —CHO, halogen, and (CH2)nC(O)NH2
• R4 is selected from the group of C1-C6 lower alkyl, C1-C6 lower alkoxy, —(CH2)n—C3-C6 cycloalkyl, —(CH2)n—S—(CH2)n—C3-C5 cycloalkyl, —(CH2)n—O—(CH2)n—C3-C5 cycloalkyl, and
• a moiety of the formulae —(CH2)n—A, —(CH2)n—S—A, or —(CH2)n—O—A, wherein A is the moiety:
• wherein
• D is H, C1-C6 lower alkyl, C1-C6 lower alkoxy, or —CF3;
• B and C are phenyl optionally substituted by from 1 to 3, substituents selected from H, halogen, —CF3, —OH, —C1-C6 alkyl, C1-C6 alkoxy, or —NO2;
• n is an integer from 0 to 3;
• R5 is a moiety selected from the formulae —L3—M3
• wherein L3 is a bridging or linking moiety selected from a chemical bond, —(CH2)n—, —S—, —O—, —SO2—, —C(O)—, —(CH2)n—C(O)—, —(CH2)n—C(O)—(CH2)n—, —(CH2)n—O—(CH2)n—, —(CH2)n—S—(CH2)n—, —C(Z)—N(R6)—, —C(Z)—N(R6)—(CH2)n—, —C(O)—C(Z)—N(R6)—, —C(O)—C(Z)—N(R6)—(CH2)n—, —C(Z)—NH—SO2—, —C(Z)—NH—SO2—(CH2)n—, —(CH2)n—S—(CH2)n—, —(CH2)n—SO—(CH2)n—, —(CH2)n—SO2—(CH2)n—, or —(CH2)n—CH═CH—(CH2)n—O—;
• Z is O or S:
• M3 is
• and n is an integer from 0 to 3;
• R9 is selected from H, halogen, —CF3, —OH, —COOH, —(CH2)n—COOH, —(CH2)n—C(O)—COOH, —C1-C16 alkyl, —O—C1-C6 alkyl, —NH(C1-C6 alkyl), or —N(C1-C6 alkyl)2;
• n is an integer from 0 to 3;
• or a pharmaceutically acceptable salt thereof.